Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.80 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28594745 | 0.92 | GSK3B (0.70) | GSK3BPTPN1 | |
| SCHEMBL689331 | 0.92 | GSK3B (0.83) | GSK3BPTPN1RAB9A | |
| SCHEMBL79354 | 0.89 | PTPN1 (1.00) | GSK3BPTPN1NPC1RAB9A | |
| SCHEMBL247615 | 0.89 | GSK3B (0.70) | GSK3BPTPN1 | |
| SCHEMBL9909658 | 0.89 | GSK3B (0.67) | GSK3BPTPN1HDAC3HDAC4HDAC1 | |
| SCHEMBL70930 | 0.89 | GSK3B (1.00) | GSK3BPTPN1HDAC3HDAC4HDAC1 | |
| SCHEMBL191879 | 0.87 | GSK3B (0.64) | GSK3BPTPN1 | |
| SCHEMBL6816324 | 0.87 | GSK3B (0.64) | GSK3BPTPN1 | |
| SCHEMBL10327311 | 0.87 | PTPN1 (1.00) | GSK3BPTPN1NPC1RAB9A | |
| SCHEMBL5804589 | 0.87 | PTPN1 (0.95) | GSK3BPTPN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0620500-A2 | Resist and pattern formation using the same | HITACHI, LTD. (JP) | 1994-10-19 | — | — | EP | claimed |
| US-4052542-A | HALO-ACETYL HIGH GREEN STRENGTH RUBBERS | POLYSAR LIMITED (CA) | 1977-10-04 | — | — | US | claimed |
| CN-113801005-B | Preparation method of alpha-bromoacetophenone compound | 浙江师范大学 | 2023-06-13 | — | — | CN | disclosed |
| CN-106588890-B | Antiviral compounds | 吉利德制药有限责任公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| EP-2107054-A1 | Antiproliferative compounds and therapeutic uses thereof | Università Degli Studi Di Milano - Bicocca (IT) | 2009-10-07 | — | — | EP | disclosed |
| EP-1410448-A1 | NOVEL PHOTOSTRUCTURABLE ORGANIC SEMICONDUCTOR MATERIALS | SIEMENS AKTIENGESELLSCHAFT (DE) | 2004-04-21 | — | — | EP | disclosed |
| EP-0911153-B1 | Image forming method | KONISHIROKU PHOTO IND (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002021611-A1 | NOVEL PHOTOSTRUCTURABLE ORGANIC SEMICONDUCTOR MATERIALS | SIEMENS AKTIENGESELLSCHAFT (DE) | 2002-03-14 | — | — | WO | disclosed |
| US-6174646-B1 | IMAGEWISE HEATING OR EXPOSING IMAGE FORMING MATERIAL TO LASER WHEREIN IMAGE FORMING MATERIAL COMPRISES SUPPORT HAVING RADIATION SENSITIVE LAYER CONTAINING DYE, AN ACID GENERATING COMPOUND CAPABLE OF GENERATING ACID ON IRRADIATION | KONICA CORPORATION (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0911153-A1 | Image forming method | KONICA CORPORATION (JP) | 1999-04-28 | — | — | EP | disclosed |
| EP-0620500-A2 | Resist and pattern formation using the same | HITACHI, LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-4505842-A | DOPED POLYOXAZOLES, -THIAZOLES AND -IMIDAZOLES; COATINGS; CASTINGS; WORKABILITY | CHEVRON RESEARCH COMPANY (US) | 1985-03-19 | — | — | US | disclosed |
| US-4249013-A | Conjugatively linked tetrathiafulvalenes and method for preparation thereof | BELL TELEPHONE LABORATORIES, INCORPORATED (US) | 1981-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | GSK3B 2041/4885PTPN1 4248/4885HDAC3 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.